Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF)
CANF moved a median of -0.48% 30 minutes after news, and -1.71% by the close. How CANF actually reacts to news — the realized, point-in-time move the market made, measured across 278 labeled events over the last three years with zero look-ahead.
CANF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 258 |
| 30-min | -0.48% | 36% | 272 |
| 60-min | -0.73% | 35% | 276 |
| to close | -1.71% | 30% | 274 |
| Middle 50% of CANF reactions | -2.77% to +0.93% |
|---|---|
| Median reaction (30-min) | -0.48% |
| Measured reactions | 278 |
Half of all Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares news events land between -2.77% and +0.93% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CANF reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 52 | +0.69% | 60% | 0.00% |
| Rating reiterations | 33 | +0.32% | 61% | -0.95% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how CANF ranks against every other measured name →
That’s how CANF usually reacts — get an email when it moves on news →Email me when CANF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CANF's baseline. Nothing else.
Recent CANF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form EFFECT Can-Fite BioPharma Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -1.01% | |
| Form F-3 Can-Fite BioPharma Ltd. | SEC filing · Form F-3 | SEC EDGAR | +0.37% | +2.20% | |
| Form F-3/A Can-Fite BioPharma Ltd. | SEC filing · Form F-3 | SEC EDGAR | +2.80% | +4.21% | |
| Form EFFECT Can-Fite BioPharma Ltd. | SEC filing · Form EFFECT | SEC EDGAR | -0.85% | -1.71% | |
| Form D Can-Fite BioPharma Ltd. | SEC filing · Form D | SEC EDGAR | -0.37% | +7.37% | |
| Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation | Press release | GlobeNewswire | +0.84% | -3.52% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | +0.84% | -3.52% | |
| Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study | Press release | GlobeNewswire | +0.44% | +1.33% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.44% | +1.33% | |
| Form POS AM Can-Fite BioPharma Ltd. | SEC filing · Form POS | SEC EDGAR | +0.84% | -3.52% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Sep 03 | SEC filing · Form 6-K | SEC EDGAR | +0.21% | -1.67% | |
| Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds | Press release | GlobeNewswire | -5.40% | -15.11% | |
| Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study | Press release | GlobeNewswire | -5.40% | -15.11% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Sep 02 | SEC filing · Form 6-K | SEC EDGAR | -5.40% | -15.11% | |
| Form F-3 Can-Fite BioPharma Ltd. | SEC filing · Form F-3 | SEC EDGAR | -2.92% | -7.02% | |
| Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer | Press release | GlobeNewswire | +0.29% | +4.99% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Aug 17 | SEC filing · Form 6-K | SEC EDGAR | +0.29% | +4.99% | |
| Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates | Press release | GlobeNewswire | -2.88% | -0.86% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Aug 12 | SEC filing · Form 6-K | SEC EDGAR | -2.88% | -0.86% | |
| Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome | Press release | GlobeNewswire | +2.88% | +1.28% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Aug 03 | SEC filing · Form 6-K | SEC EDGAR | +2.88% | +1.28% | |
| Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology | Press release | GlobeNewswire | -0.88% | -3.22% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Jul 20 | SEC filing · Form 6-K | SEC EDGAR | -0.88% | -3.22% | |
| Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer | Press release | GlobeNewswire | -2.31% | -6.94% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Jul 14 | SEC filing · Form 6-K | SEC EDGAR | -2.31% | -6.94% | |
| Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 | Press release | GlobeNewswire | +0.26% | -2.31% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Jul 06 | SEC filing · Form 6-K | SEC EDGAR | +0.26% | -2.31% | |
| Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease | Press release | GlobeNewswire | -0.60% | -7.77% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Jul 01 | SEC filing · Form 6-K | SEC EDGAR | -0.60% | -7.77% | |
| Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology | Press release | GlobeNewswire | +1.52% | -16.92% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Jun 26 | SEC filing · Form 6-K | SEC EDGAR | +1.52% | -16.92% | |
| Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Jun 22 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.00% | |
| Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 | Press release | GlobeNewswire | +0.00% | +1.00% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Jun 17 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +1.00% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Jun 04 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -3.44% | |
| Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism | Press release | GlobeNewswire | +0.00% | -2.81% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Jun 02 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -2.81% | |
| Form 6-K Can-Fite BioPharma Ltd. For: May 28 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.30% | |
| Form 6-K Can-Fite BioPharma Ltd. For: May 18 | SEC filing · Form 6-K | SEC EDGAR | +2.17% | -5.78% | |
| Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market | Press release | GlobeNewswire | +2.17% | -5.78% | |
| Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy | Press release | GlobeNewswire | +0.29% | +5.81% | |
| Form 6-K Can-Fite BioPharma Ltd. For: May 13 | SEC filing · Form 6-K | SEC EDGAR | +0.29% | +5.81% | |
| Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months | Press release | GlobeNewswire | -2.74% | -12.60% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | -2.74% | -12.60% | |
| Form 6-K Can-Fite BioPharma Ltd. For: Apr 23 | SEC filing · Form 6-K | SEC EDGAR | +3.60% | -0.68% | |
| Form EFFECT Can-Fite BioPharma Ltd. | SEC filing · Form EFFECT | SEC EDGAR | — | -1.29% | |
| Form EFFECT Can-Fite BioPharma Ltd. | SEC filing · Form EFFECT | SEC EDGAR | — | +0.00% | |
| Form F-3 Can-Fite BioPharma Ltd. | SEC filing · Form F-3 | SEC EDGAR | -0.67% | +4.03% | |
| Form POS AM Can-Fite BioPharma Ltd. | SEC filing · Form POS | SEC EDGAR | -0.67% | +4.03% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CANF section they belong to.
Where else CANF is measured.
CANF earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | 279 | -0.52% | 36% |
| CORREVIO PHARMA CORP ORDINARY SHARES (CORV) | 279 | 0.00% | 44% |
| AtriCure, Inc. (ATRC) | 276 | +0.04% | 51% |
| Coherus Oncology, Inc. (CHRS) | 276 | +0.21% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares's median reaction calculated?
Every labeled CANF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 278 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of CANF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CANF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.